Mother’s Six-Year Quest for Justice After Daughter’s Death by Bad Medicine

An Indian pharmaceutical company, Naprod, is facing scrutiny over the distribution of contaminated cancer medications that resulted in the deaths of four children in Colombia in 2020. The controversy centers on the company’s continued global export operations despite regulatory findings of contamination.

According to reporting by The Bureau Investigates, the Colombian regulator identified that Naprod’s drugs were contaminated. However, the regulator only ordered a recall of the medication after it was too late to prevent several fatalities.

Impact of Contaminated Medication

The contaminated drugs included methotrexate, a medication used in the treatment of aggressive forms of leukaemia. In one documented case, Valery Javiana Fernández Rivas, a six-year-old patient, received a spinal injection of the drug at Clínica Medical Duarte in Cúcuta in late January 2020.

Following the injection, the patient experienced severe pain and vomiting, entered a coma four days later, and died approximately two weeks after the administration of the drug.

Valery was one of four children who died in 2020 after receiving cancer drugs manufactured by Naprod. More than 100 other patients suffered reactions that medical professionals suspected were linked to the contaminated medicine.

Regulatory and Legal Failures

Despite the deaths and the findings of the Colombian regulator, investigations within Colombia have not produced results for the affected families. The families of the deceased children have called for justice, but little progress has been made in the six years since the events began.

A critical point of failure identified in the reporting is the timing of the regulatory response. The Colombian regulator’s decision to order a recall only after the contamination had already caused fatalities suggests a gap in the oversight of imported pharmaceuticals.

Corporate Continuity and Global Trade

Despite the contamination findings and the resulting deaths in Colombia, Naprod has not ceased its operations. The company continues to export medicines to various markets around the world, including continuing its exports to Colombia.

This situation highlights significant challenges in the regulation of the global pharmaceutical supply chain, particularly regarding the quality control of vital medications produced in India for international markets.

The case underscores the tension between the need for affordable, vital drugs and the necessity of rigorous safety standards to prevent contaminated products from reaching patients in foreign jurisdictions.